Yusibov Vidadi, Rabindran Shailaja
Fraunhofer USA Center for Molecular Biotechnology, 9 Innovation Way, Suite 200, Newark, DE 1971, USA.
Expert Rev Vaccines. 2008 Oct;7(8):1173-83. doi: 10.1586/14760584.7.8.1173.
Recombinant subunit vaccines have been with us for the last 30 years and they provide us with the unique opportunity to choose from the many available production systems that can be used for recombinant protein expression. Plants have become an attractive production platform for recombinant biopharmaceuticals and vaccines have been at the forefront of this new and expanding industry sector. The particular advantages of plant-based vaccines in terms of cost, safety and scalability are discussed in the light of recent successful clinical trials and the likely impact of plant systems on the vaccine industry is evaluated.
重组亚单位疫苗已经陪伴我们走过了30年，它们为我们提供了独特的机会，可以从许多可用于重组蛋白表达的生产系统中进行选择。植物已成为重组生物制药的一个有吸引力的生产平台，疫苗一直处于这个新兴且不断发展的行业领域的前沿。鉴于最近的成功临床试验，讨论了基于植物的疫苗在成本、安全性和可扩展性方面的特殊优势，并评估了植物系统对疫苗行业可能产生的影响。
